## **Announcing Regional Workshops on**

# STABILITY TESTING AND CONTROL

## **Avoiding Stability Problems**

New Jersey	Puerto Rico	<u>Missouri</u>	<u>California</u>
June 28. 1999  Completed.  Me Successful el  Eas Meeting!	July 19. 1999  Completed. Successful Meeting!	August 2, 1999 St. Louis Marriott Pavilion Hotel St. Louis, MO 314-421-1776	August 16, 1999 Manhattan Beach Marriott Hotel Manhattan Beach, CA 310-546-7511

## Presented by:

Consumer Healthcare Products Association (CHPA)
Food and Drug Administration (FDA)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Generic Pharmaceutical Industry Association (GPIA)
National Association of Pharmaceutical Manufacturers (NAPM)
National Pharmaceutical Alliance (NPA)
United States Pharmacopeia (USP)

Stability and stability-related issues have been the prominent cause of drug product recalls in the past two years. Through this joint FDA/industry educational program, the root causes of these recalls will be addressed, and experienced experts will provide solutions.

The educational workshops will address a broad range of issues related to stability. Both FDA and industry speakers will be featured at the workshops. FDA and the associations are encouraging broad attendance from pharmaceutical companies of all sizes. To help make it easy, the registration fee is being held to only \$250 per person, including lunch, and the workshops will be presented four times, in the East, the Midwest, the West, and Puerto Rico, all in the summer of 1999. Further details are on the following pages.

## STABILITY TESTING AND CONTROL FACULTY

Mark S. Alasandro Associate Director Analytical R & D

**DuPont Life Sciences Enterprise** 

Kevin Bradley

Manager, Support to Marketed Products - Analytical

McNeil Consumer Healthcare

William W. Bradley

Vice President – Technical Affairs

Consumer Healthcare Products Association

Scott Buell, Ph.D. & (St. Louis)

Manager, Quality Control Analytical Services

Glaxo Wellcome Inc.

Carol Easter (Panel)

Senior Manager, Stability Operations

Merck & Co., Inc.

John Ferrantello

Associate Director of Stability Services

Research & Technology

Block Drug Company, Inc

Kenneth J. Furnkranz \*(Puerto Rico)

Chemist, Office of Generic Drugs

Food and Drug Administration

Nirdosh K. Jagota, Ph.D. & (California)

Associate Director

CMC & International Registration

**Drug Regulatory Affairs** 

Sanofi Pharmaceuticals, Inc.

James I. Giefer (St. Louis)

Drug Investigator

Kansas City District

Food and Drug Administration

Jorge L. Gonzalez (Puerto Rico)

Drug Investigator San Juan District

Food and Drug Administration

Lee T. Grady + (Puerto Rico, St. Louis)

Vice President and Director

Division of Standards Development

United States Pharmacopeial Convention

Ali H. Al Hakim, Ph.D. \* (St. Louis) Chemist, Office of New Drug Chemistry

Food and Drug Administration

Lori S. Henning **♣** (*Puerto Rico*)

Director, Compendial Documentation

Wyeth-Ayerst Global Pharmaceuticals

Robert V. Kasubick, Ph.D.

Vice President of Operations

Oakwood Laboratories, L.L.C.

Herbert Letterman, Ph.D. + (New Jersey, California)

Consultant

Member of the Advisory Committee to the USP PDS Subcommittee

Jai Mehta

President

**JMPharma** 

Abita Nanda (New Jersey)

Field Investigator

New Jersey District

Food and Drug Administration

Virgilio F. Pacio (California)

Drug Investigator

Los Angeles District

Food and Drug Administration

Shrikant N. Pagay, Ph.D. \* (California)

Chemist, Office of New Drug Chemistry

Food and Drug Administration

Holly J. Perpall, Ph.D. (New Jersey)

**Associate Director** 

Regulatory and Analytical Sciences - Stability Department

Merck & Co., Inc.

Barry Rothman

Office of Compliance

Center for Drug Evaluation and Research

Food and Drug Administration

Robert H. Seevers, Ph.D., \* (New Jersey)

Chemist, Office of New Drug Chemistry

Chairperson of the CDER Stability Committee

Food and Drug Administration

The Food and Drug Administration, along with the USP and the five most representative drug trade associations is presenting an educational series on important aspects of stability. Whether you are new to the filed of stability testing and evaluation, or have vast experience in the area, you and your company can benefit from this workshop. You will not only hear about the stability controversy, you will be able to interact with key FDA officials and industry experts, and give your own opinions.

#### The educational objectives of the workshops are to:

- ♦ Learn all about the FDA Draft Guidance for Industry on Stability
- ♦ Learn how to make sure your methods are stability indicating
- Learn different methods for establishing an expiry date
- ♦ Learn when, and when not, to use the Arrhenius equation
- ♦ Learn the stability issues surfacing in the United States Pharmacopeia
- ♦ Learn what FDA sees as stability problems
- Learn how to control factors that affect stability, and avoid recalls
- Learn how to label your products for storage to comply with various rules and regulations
- Learn how to avoid stability problems with your products

#### STABILITY TESTING AND CONTROL

#### **Avoiding Stability Problems**

### **Program**

8:00 a.m. Welcomes and Introductions William W. Bradley Vice President – Technical Affairs
Consumer Healthcare Products Association FDA District Director 8:10 a.m. FDA Draft Stability Guidance for Industry Representative from Stability Coordinating Committee Center for Drug Evaluation & Research Food and Drug Administration 9:00 a.m. **Practical Considerations** Hybrid conditions John Ferrantello Associate Director of Stability Services Research & Technology Block Drug Company, Inc. Packaging considerations Kevin Bradley Manager, Support to Marketed Products - Analytical McNeil Consumer Healthcare Stability-indicating test methods Mark S. Alasandro Associate Director, Analytical R&D DuPont Life Sciences Enterprise Use of the Arrhenius equation Robert Kasubick, Ph.D. Vice President of Operations Oakwood Laboratories, L.L.C. **BREAK** 10:00 a.m. USP Stability and Storage Issues 10:30 a.m. Lee T. Grady Vice President and Director Division of Standards Development United States Pharmacopeial Convention 11:15 a.m. Round Table Discussion and Q&A FDA, USP, Industry Representatives 12:00 noon LUNCH 1:15 p.m. Background on Stability Compliance Problems Barry Rothman Office of Compliance Center for Drug Evaluation and Research Food and Drug Administration FDA Field Investigator 2:15 p.m. Controlling Factors that Affect Stability Speakers for this subject will differ by location. They are identified by the symbol . on the faculty list 2:40 p.m. **BREAK** 3:00 p.m. Label Storage Statements and Stability Jai Mehta President JM Pharma Panel Discussion and Q&A 3:20 p.m. All Speakers 4:30 p.m. Adjournment

#### STABILITY TESTING AND CONTROL

**Avoiding Stability Problems** 

#### Who Should Attend

- Regulatory managers
- Those with responsibility for:
  - NDA compilation
  - setting expiry dates
  - stability testing
  - stability evaluation
  - ensuring stability
  - labeling
  - problem solving
  - writing SOPs

**GET HOTEL** RESERVATIONS IN EARLY!

### **New Jersey** June 28, 1999

ls.

Completed. Successful Meeting!

## **Puerto Rico** July 19, 1999

Completed. Successful Meeting!

rax /o/-ooo-0000

### Missouri August 2, 1999

St. Louis Marriott Pavilion Hotel St. Louis, MO Ph. 314-421-1776

Fax 314-331-9269

## California

August 16, 1999 Manhattan Beach Marriott Hotel Manhattan Beach, CA Ph. 310-546-7511 Fax 310-796-0322

### Stability Testing and Control

Registration Form (Please print or type)

No phone registrations, please. No refunds will be made after 2 weeks prior to the workshop. Substitutions will be accepted. Contact hotel directly for room reservations.

MAKE CHECKS PAYABLE TO CHPA For your convenience, CHPA accepts MasterCard, VISA, and American Express credit cards. Mail or fax completed registration form with your payment to:

Mary McDonald **CHPA** 1150 Connecticut Ave., N.W. Washington, DC 20036

> Phone 202-429-9260 Fax 202-223-6835

Registration fee: \$250.00

	on card:			
Signature				
Credit card #		Exp. Date		
□ VISA	■ MasterCard		☐ Check	
E-mail				
Phone	Fax	κ		
City		State	_Zip	
	·			
	e) Tit			
name				

I am registering for (please ✓ one)

Sheraton Meadowlands 201/896-0500

Westin Rio Mar Beach Resort 787/888-6612

Marriott Pavilion Hotel 314/421-1776

☐ June 28, East Rutherford, NJ; ☐ July 19, Rio Grande, PR; ☐ August 2, St. Louis, MO; ☐ August 16, Manhattan Beach, CA Manhattan Beach Marriott 310/546-7511